Welcome, friends. This inaugural edition of the ForeverLabs blog will attempt to help you make sense of our company, our mission, and why you should continue to check our blog from time to time.
What’s the deal with lifespan. A lot of attention has been paid recently to the life-lengthening capabilities of blood and bone marrow collected from young mice, when injected to older mice.
Aren't iPS cells the future. When talking to friends, colleagues, and others about Forever Labs, those among them with a certain level of knowledge in the biosciences often turn the conversation to iPS cells.
What is a stem cell anyway. As a biologist, and one who works with bone marrow stem cells in daily life, it’s easy to forget that to the general public, a ‘stem cell’ is not much more than an abstraction, a news-worthy meme that comes light on the details.
New Studies Show How Donor Age Affects MSCs’ Disease Fighting Capabilities
New Studies Show How Donor Age Affects MSCs’ Disease Fighting Capabilities
In the past, I’ve written that there is a strong suggestion that MSCs from older individuals are less likely than those from young ones to fight diseases, but that the evidence—though strong—is mainly circumstantial. However, two very recent studies have shown direct and convincing evidence that this is indeed the case.
How young blood might help reverse aging. Yes, really
How young blood might help reverse aging. Yes, really
Tony Wyss-Coray on TED Talk
In this TED talk, Tony Wyss-Coray studies the impact of aging on the human body and brain.
Why your own cells matter
Many people have asked us, “Can I use my cells for a family member?” Strictly speaking, you may be able to for some conditions, some of the time. But here, I’d like to discuss why your cells matter to you more than to anyone else.
Stroke trial finally published
The long awaited results of a bone marrow MSC stroke trial were published recently, and the results were quite striking (with caveats that we’ll get to). This topic is near and dear to my heart, as using MSCs for stroke recovery is my field of expertise, and the preclinical work that led to this trial was pioneered by my mentors.
